MA38657A1 - Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer - Google Patents

Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer

Info

Publication number
MA38657A1
MA38657A1 MA38657A MA38657A MA38657A1 MA 38657 A1 MA38657 A1 MA 38657A1 MA 38657 A MA38657 A MA 38657A MA 38657 A MA38657 A MA 38657A MA 38657 A1 MA38657 A1 MA 38657A1
Authority
MA
Morocco
Prior art keywords
cancer
combination
treatment
mitotic agent
imidazopyridazine derivative
Prior art date
Application number
MA38657A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48578942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38657(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38657A1 publication Critical patent/MA38657A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une combinaison comprenant un inhibiteur de la mps-1 kinase et un inhibiteur de la mitose. La présente invention concerne également l'utilisation de ladite combinaison pour le traitement d'un cancer, en particulier du cancer du pancréas, d'un glioblastome, du cancer de l'ovaire, d'un carcinome pulmonaire non à petites cellule, du cancer du sein et/ou du cancer gastrique.
MA38657A 2013-06-13 2014-06-11 Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer MA38657A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171818 2013-06-13
PCT/EP2014/062133 WO2014198776A1 (fr) 2013-06-13 2014-06-11 Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA38657A1 true MA38657A1 (fr) 2018-05-31

Family

ID=48578942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38657A MA38657A1 (fr) 2013-06-13 2014-06-11 Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer

Country Status (17)

Country Link
US (1) US20160175306A1 (fr)
EP (1) EP3007698A1 (fr)
JP (1) JP2016521740A (fr)
KR (1) KR20160018749A (fr)
CN (1) CN105392484A (fr)
AP (1) AP2015008915A0 (fr)
AU (1) AU2014280224A1 (fr)
CA (1) CA2914995A1 (fr)
CL (1) CL2015003606A1 (fr)
EA (1) EA028800B1 (fr)
HK (1) HK1222341A1 (fr)
MA (1) MA38657A1 (fr)
MX (1) MX2015017245A (fr)
PH (1) PH12015502756A1 (fr)
SG (1) SG11201510034QA (fr)
TN (1) TN2015000544A1 (fr)
WO (1) WO2014198776A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2013135612A1 (fr) * 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Imidazopyridazines substituées
WO2014020041A1 (fr) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□

Also Published As

Publication number Publication date
TN2015000544A1 (en) 2017-04-06
PH12015502756A1 (en) 2016-03-14
CN105392484A (zh) 2016-03-09
KR20160018749A (ko) 2016-02-17
MX2015017245A (es) 2016-07-20
WO2014198776A1 (fr) 2014-12-18
US20160175306A1 (en) 2016-06-23
EP3007698A1 (fr) 2016-04-20
AP2015008915A0 (en) 2015-12-31
CL2015003606A1 (es) 2016-08-12
HK1222341A1 (zh) 2017-06-30
CA2914995A1 (fr) 2014-12-18
SG11201510034QA (en) 2016-01-28
JP2016521740A (ja) 2016-07-25
EA201600014A1 (ru) 2016-06-30
AU2014280224A1 (en) 2016-01-07
EA028800B1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
MA39034B1 (fr) Composés de quinoline sélectivement substitués
TR201812261T4 (tr) Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
EP3934645A4 (fr) Utilisation du catequentinib (anlotinib) en combinaison avec une chimiothérapie standard ou une immunothérapie standard pour le traitement du cancer
TN2018000044A1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
MX395149B (es) Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
UA117470C2 (uk) Заміщені ксантини та способи їх застосування
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
MY173126A (en) Arylquinazolines
MX2017012613A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
MA38656A1 (fr) Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
MX374785B (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
MX375325B (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
WO2013106747A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer de la thyroïde
BR112015016995A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral
BR112015016992A8 (pt) uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
FR3082427B1 (fr) Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x